Stop the resignations! Make salaries right!!!

[anonymous]

Man that district is down to a couple TMs and they got a new RSM. Lots of vacancies to fill there and nationwide. I’m glad I’m not on biologics. What a disaster.

It’s tough on biologics. Every section of that division has had resignations on all levels. A relaunch is what Iluyma needs but a relaunch screams major problems within company.

 

[anonymous]

It’s tough on biologics. Every section of that division has had resignations on all levels. A relaunch is what Iluyma needs but a relaunch screams major problems within company.

It’s a shit show

 

[anonymous]

It’s a shit show

What more honestly needs to be said? A shit show from top to bottom and in the parking lot.

 

[anonymous]

Relaunches are never as successful as everyone thinks. This place is an epic fucking disaster. Remember for the TM’s that are still here aren’t working much at all.

 

[anonymous]

Those TM's are still waiting for a miracle.

 

[anonymous]

Relaunches are never as successful as everyone thinks. This place is an epic fucking disaster. Remember for the TM’s that are still here aren’t working much at all.

How do they not track that they are not working?

 

[anonymous]

Relaunches are never as successful as everyone thinks. This place is an epic fucking disaster. Remember for the TM’s that are still here aren’t working much at all.

Wrong.
Relaunches are virtually never a success but rather a further drain on the company.
Many a data and case studies that show the product revenue/share lifecycle is set in the first six months. Almost never-ever does that trajectory change.
#piglipstick
#stillapig

 

[anonymous]

Wrong.
Relaunches are virtually never a success but rather a further drain on the company.
Many a data and case studies that show the product revenue/share lifecycle is set in the first six months. Almost never-ever does that trajectory change.
#piglipstick
#stillapig

Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.

 

[anonymous]

Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.

Fix the HUB and you have fixed 80% of the problem. You can gain share (call it re-launch or anything else) if access is up to standard. Bad coverage and a lousy HUB equals no improvement over current mediocre.

 

[anonymous]

So that begs the question-Why the hell are you still here?

 

[anonymous]

Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.

If Merck were to re-launch Ilumya, then success might be possible.

 

[anonymous]

Didn't we already relaunch the HUB once?

 

[anonymous]

Didn't we already relaunch the HUB once?

Two or three times with all new people!

 

[anonymous]

Two or three times with all new people!

Embarrassing!

 

[anonymous]

Didn't we already relaunch the HUB once?

We did relaunch the HUB once before. It went something like this:
“Those sales people are bad. There will be no changes to the HUB. The only changes will be to the sales force.”
Well done and mission accomplished.